Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/9032
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLagos, K. G.en
dc.contributor.authorFilippatos, T. D.en
dc.contributor.authorTsimihodimos, V.en
dc.contributor.authorGazi, I. F.en
dc.contributor.authorRizos, C.en
dc.contributor.authorTselepis, A. D.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T16:46:07Z-
dc.date.available2015-11-24T16:46:07Z-
dc.identifier.issn0024-4201-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/9032-
dc.rightsDefault Licence-
dc.subjectmetabolic syndromeen
dc.subjecthigh density lipoproteinen
dc.subjectsubclassesen
dc.subjectlipoprotein associated phospholipase a(2)en
dc.subjectparaoxonase 1en
dc.subjecthigh sensitivity c-reactive proteinen
dc.subjectsmall dense low density lipoprotein cholesterolen
dc.subjecttriglyceridesen
dc.subjectactivating-factor-acetylhydrolaseen
dc.subjectelevated oxidative stressen
dc.subjectcoronary-heart-diseaseen
dc.subjectphospholipase a(2)en
dc.subjectdiabetes-mellitusen
dc.subjectantioxidative activityen
dc.subjectcardiovascular eventsen
dc.subjectparaoxonase activityen
dc.subjectclinical importanceen
dc.subjectintervention trialen
dc.titleAlterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndromeen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primaryDOI 10.1007/s11745-008-3251-9-
heal.identifier.secondary<Go to ISI>://000261790800002-
heal.identifier.secondaryhttp://www.springerlink.com/content/5255503v08850n22/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.publicationDate2009-
heal.abstractPatients with metabolic syndrome (MetS) usually have low high density lipoprotein cholesterol (HDL-C) levels. We determined the HDL distribution profile as well as the HDL-related lipoprotein associated phospholipase A(2) (HDL-LpPLA(2)) and paraoxonase-1 (PON1) activities in subjects with MetS (n = 189) but otherwise healthy. Age and sex-matched individuals (n = 166) without MetS served as controls. The lower HDL-C concentration in MetS patients was due to a reduction in both large and small HDL subclasses (P < 0.001 and P < 0.05, respectively). As the number of MetS components increased, the HDL phenotype comprised of a greater percentage of small HDL-3 and less large HDL-2 subclasses, resulting in a decreased HDL-2/HDL-3 ratio (P < 0.001 for all trends). Multivariate analysis revealed that HDL-2 levels and the HDL-2/HDL-3 ratio significantly and independently correlated with HDL-C (positively) and TG (negatively) levels. HDL-3 concentration significantly and independently positively correlated with HDL-C and TG levels. HDL-LpPLA(2) activity was decreased in MetS patients (P < 0.01), a phenomenon that may contribute to the defective antiatherogenic activity of HDL in MetS. PON1 activity did not differ between groups. We conclude that MetS, in addition to the decrease in HDL-C concentration, is associated with alterations in the HDL phenotype, which is comprised of a greater percentage of small HDL subclasses. Furthermore, HDL-LpPLA(2) activity is decreased in MetS patients.en
heal.journalNameLipidsen
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ

Files in This Item:
File Description SizeFormat 
Lagos-2009-Alterations in the H.pdf227.93 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons